Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Astera Labs, Inc.ALAB · Entity 1853 | Director | June 04, 2026 | June 09, 2026 |
| BOX INCBOX · Entity 3932 | Director | June 25, 2026 | June 29, 2026 |
| GLOBALFOUNDRIES Inc.GFS · Entity 3198 | Director | July 29, 2026 | July 31, 2026 |
| RESIDEO TECHNOLOGIES, INC.REZI · Entity 1292 | Director | October 01, 2026 | October 05, 2026 |
| SILICON LABORATORIES INC.SLAB · Entity 3682 | Director | September 01, 2021 | September 03, 2021 |
| ThredUp Inc.TDUP · Entity 1057 | Director | September 03, 2024 | September 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Astera Labs, Inc.
Report date June 04, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,688 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 837 · Balance 85,688 F1: These shares represent an award of restricted stock units ("RSUs") granted on June 4, 2026 (the "Grant Date") under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award vests in full upon the earlier of (i) the first anniversary of the Grant Date or (ii) the date of the next annual stockholder meeting of the Company following the Grant Date, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 84,809 |
Reported balance
After 2026-06-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-04 · Sale · Disposed 879 · Balance 84,809 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $362.5300 to $363.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 83,955 |
Reported balance
After 2026-06-04 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-06-04 · Sale · Disposed 854 · Balance 83,955 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $360.8100 to $361.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 82,839 |
Reported balance
After 2026-06-04 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-06-04 · Sale · Disposed 1,116 · Balance 82,839 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $359.7450 to $360.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 81,962 |
Reported balance
After 2026-06-04 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-06-04 · Sale · Disposed 877 · Balance 81,962 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $358.8000 to $359.6400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 81,079 |
Reported balance
After 2026-06-04 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-06-04 · Sale · Disposed 883 · Balance 81,079 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $357.8650 to $358.6000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 80,513 |
Reported balance
After 2026-06-04 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2026-06-04 · Sale · Disposed 566 · Balance 80,513 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $356.6600 to $357.5750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 79,567 |
Reported balance
After 2026-06-04 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2026-06-04 · Sale · Disposed 946 · Balance 79,567 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.6200 to $355.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 79,194 |
Reported balance
After 2026-06-04 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2026-06-04 · Sale · Disposed 373 · Balance 79,194 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.0600 to $354.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 78,093 |
Reported balance
After 2026-06-04 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2026-06-04 · Sale · Disposed 1,101 · Balance 78,093 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F12: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $352.5400 to $353.5200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 77,775 |
Reported balance
After 2026-06-04 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2026-06-04 · Sale · Disposed 318 · Balance 77,775 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F13: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $351.5250 to $352.4850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 77,758 |
Reported balance
After 2026-06-04 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2026-06-04 · Sale · Disposed 17 · Balance 77,758 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 77,335 |
Reported balance
After 2026-06-04 transaction · row 13
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 13 · 2026-06-04 · Sale · Disposed 423 · Balance 77,335 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F14: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $349.1050 to $350.0100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 77,142 |
Reported balance
After 2026-06-04 transaction · row 14
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 14 · 2026-06-04 · Sale · Disposed 193 · Balance 77,142 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F15: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.7700 to $347.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 76,904 |
Reported balance
After 2026-06-04 transaction · row 15
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 15 · 2026-06-04 · Sale · Disposed 238 · Balance 76,904 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F16: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.2700 to $346.6650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 76,658 |
Reported balance
After 2026-06-04 transaction · row 16
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 16 · 2026-06-04 · Sale · Disposed 246 · Balance 76,658 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F17: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.6650 to $345.6250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 76,415 |
Reported balance
After 2026-06-04 transaction · row 17
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 17 · 2026-06-04 · Sale · Disposed 243 · Balance 76,415 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F18: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $343.9250 to $344.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: Includes deferred stock units and dividend equivalent units. |
| Common StockSEC Table I · non-derivative | Direct | 75,888 |
Reported balance
After 2026-06-04 transaction · row 18
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 18 · 2026-06-04 · Sale · Disposed 527 · Balance 75,888 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F19: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 75,688 |
Reported balance
After 2026-06-04 transaction · row 19
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 19 · 2026-06-04 · Sale · Disposed 200 · Balance 75,688 F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F19: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent an award of restricted stock units ("RSUs") granted on June 4, 2026 (the "Grant Date") under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award vests in full upon the earlier of (i) the first anniversary of the Grant Date or (ii) the date of the next annual stockholder meeting of the Company following the Grant Date, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Includes deferred stock units and dividend equivalent units.
F3: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $362.5300 to $363.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $360.8100 to $361.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $359.7450 to $360.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $358.8000 to $359.6400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $357.8650 to $358.6000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $356.6600 to $357.5750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.6200 to $355.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.0600 to $354.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F12: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $352.5400 to $353.5200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F13: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $351.5250 to $352.4850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F14: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $349.1050 to $350.0100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F15: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.7700 to $347.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F16: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.2700 to $346.6650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F17: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.6650 to $345.6250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F18: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $343.9250 to $344.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F19: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
BOX INC
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 33,727 |
Reported balance
After 2026-06-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 8,372 · Balance 33,727 F1: Represents an annual restricted stock unit ("RSU") award pursuant to the Issuer's Outside Director Compensation Policy. Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. 100% of the RSUs will vest on the earlier of (i) twelve months from date of grant (i.e. June 25, 2027) or (ii) the date of the Issuer's next annual meeting of stockholders. F2: Certain of these shares are represented by RSUs. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer subject to the applicable vesting schedule and the Reporting Person's continuous service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual restricted stock unit ("RSU") award pursuant to the Issuer's Outside Director Compensation Policy. Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. 100% of the RSUs will vest on the earlier of (i) twelve months from date of grant (i.e. June 25, 2027) or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: Certain of these shares are represented by RSUs. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer subject to the applicable vesting schedule and the Reporting Person's continuous service through each such date.
GLOBALFOUNDRIES Inc.
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 3,291 |
Reported balance
Holding disclosure · report date 2026-07-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,291 F1: Reflects the vesting and settlement of restricted stock units (RSUs) into 5,567 ordinary shares on July 29, 2026. F2: Represents 3,291 RSUs, which vest on July 28, 2027, subject to the reporting person's continued service through the vesting date. Each RSU represents a contingent right to receive one share of the issuer's ordinary shares upon settlement. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 28,094 |
Reported balance
Holding disclosure · report date 2026-07-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28,094 F1: Reflects the vesting and settlement of restricted stock units (RSUs) into 5,567 ordinary shares on July 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the vesting and settlement of restricted stock units (RSUs) into 5,567 ordinary shares on July 29, 2026.
F2: Represents 3,291 RSUs, which vest on July 28, 2027, subject to the reporting person's continued service through the vesting date. Each RSU represents a contingent right to receive one share of the issuer's ordinary shares upon settlement.
RESIDEO TECHNOLOGIES, INC.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,680 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,811 · Balance 126,680 F1: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant. F2: Reflects 1,681 restricted stock units acquired pursuant to exempt anti-dilution adjustments in connection with the spin-off of ADI Global Distribution Inc. from Resideo Technologies, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant.
F2: Reflects 1,681 restricted stock units acquired pursuant to exempt anti-dilution adjustments in connection with the spin-off of ADI Global Distribution Inc. from Resideo Technologies, Inc.
SILICON LABORATORIES INC.
Report date September 01, 2021 · Filed September 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 10,466 |
Reported balance
After 2021-09-01 transaction · row 1
1 source rowRow 1 · 2021-09-01 · Sale · Disposed 1,353 · Balance 10,466 |
ThredUp Inc.
Report date September 03, 2024 · Filed September 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 298,258 |
Reported balance
After 2024-09-03 transaction · row 1
1 source rowRow 1 · 2024-09-03 · Purchase · Acquired 20,000 · Balance 298,258 F1: Open market purchase of shares in accordance with Issuer's trading policies. F2: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.9301 to $0.9584 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase of shares in accordance with Issuer's trading policies.
F2: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.9301 to $0.9584 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Casper Sleep Inc.
Report date January 25, 2022 · Filed January 26, 2022
Section 16 reporting ended · disclosed 2022-01-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-01-25 transaction · row 1
1 source rowRow 1 · 2022-01-25 · Disposition to issuer · Disposed 50,060 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2021 (the "Merger Agreement"), by and among Casper Sleep Inc. (the "Issuer"), Marlin Parent, Inc. and Marlin Merger Sub, Inc. ("Merger Sub"). On January 25, 2022, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.000001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $6.90 (the "Merger Consideration"), without interest, subject to applicable withholding taxes. F2: In accordance with the Merger Agreement, each restricted stock unit award ("RSU Award") of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was cancelled and converted into the right to receive an amount in cash, subject to applicable withholding taxes, equal to the Merger Consideration multiplied by the number of shares of Issuer common stock subject to such RSU Award. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.90 · Expires 2029-04-11 | Direct | 0 |
Reported balance
After 2022-01-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-25 · Disposition to issuer · Disposed 1,517 · Balance 0 F4: In accordance with the Merger Agreement, each option to acquire common stock of the Issuer that was unvested or had a per share exercise price equal to or greater than the Merger Consideration was cancelled for no consideration as of the effective time of the Merger. F3: The options were fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2028-06-25 | Direct | 0 |
Reported balance
After 2022-01-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-25 · Disposition to issuer · Disposed 2,260 · Balance 0 F4: In accordance with the Merger Agreement, each option to acquire common stock of the Issuer that was unvested or had a per share exercise price equal to or greater than the Merger Consideration was cancelled for no consideration as of the effective time of the Merger. F3: The options were fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.90 · Expires 2029-03-11 | Direct | 0 |
Reported balance
After 2022-01-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-01-25 · Disposition to issuer · Disposed 3,222 · Balance 0 F4: In accordance with the Merger Agreement, each option to acquire common stock of the Issuer that was unvested or had a per share exercise price equal to or greater than the Merger Consideration was cancelled for no consideration as of the effective time of the Merger. F3: The options were fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.90 · Expires 2029-04-11 | Direct | 0 |
Reported balance
After 2022-01-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-25 · Disposition to issuer · Disposed 60,000 · Balance 0 F4: In accordance with the Merger Agreement, each option to acquire common stock of the Issuer that was unvested or had a per share exercise price equal to or greater than the Merger Consideration was cancelled for no consideration as of the effective time of the Merger. F5: The options provided for vesting in equal monthly installments over a four year period commencing on May 12, 2019, and would have been fully vested and exercisable on April 12, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2021 (the "Merger Agreement"), by and among Casper Sleep Inc. (the "Issuer"), Marlin Parent, Inc. and Marlin Merger Sub, Inc. ("Merger Sub"). On January 25, 2022, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.000001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $6.90 (the "Merger Consideration"), without interest, subject to applicable withholding taxes.
F2: In accordance with the Merger Agreement, each restricted stock unit award ("RSU Award") of the Issuer outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was cancelled and converted into the right to receive an amount in cash, subject to applicable withholding taxes, equal to the Merger Consideration multiplied by the number of shares of Issuer common stock subject to such RSU Award.
F3: The options were fully vested and exercisable.
F4: In accordance with the Merger Agreement, each option to acquire common stock of the Issuer that was unvested or had a per share exercise price equal to or greater than the Merger Consideration was cancelled for no consideration as of the effective time of the Merger.
F5: The options provided for vesting in equal monthly installments over a four year period commencing on May 12, 2019, and would have been fully vested and exercisable on April 12, 2023.
Mellanox Technologies, Ltd.
Report date April 27, 2020 · Filed April 27, 2020
Section 16 reporting ended · disclosed 2020-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-04-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-04-27 · Disposition to issuer · Disposed 6,449 · Balance 633 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as March 10, 2019 (the "Merger Agreement"), by and among the Issuer, NVIDIA International Holdings, Inc., a Delaware corporation ("Parent"), Teal Barvaz Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Parent, and NVIDIA Corporation, a Delaware corporation in exchange for cash consideration of $125.00 per share (the "Per Share Merger Consideration"), subject to any applicable withholding taxes. Row 2 · 2020-04-27 · Disposition to issuer · Disposed 633 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, on April 27, 2020, each outstanding award of restricted stock units ("Issuer RSU") that either (i) had fully vested but had not yet settled in shares or (ii) was held by a non-employee director of the Issuer, whether vested or unvested, was cancelled in exchange for the Per Share Merger Consideration less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as March 10, 2019 (the "Merger Agreement"), by and among the Issuer, NVIDIA International Holdings, Inc., a Delaware corporation ("Parent"), Teal Barvaz Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Parent, and NVIDIA Corporation, a Delaware corporation in exchange for cash consideration of $125.00 per share (the "Per Share Merger Consideration"), subject to any applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, on April 27, 2020, each outstanding award of restricted stock units ("Issuer RSU") that either (i) had fully vested but had not yet settled in shares or (ii) was held by a non-employee director of the Issuer, whether vested or unvested, was cancelled in exchange for the Per Share Merger Consideration less any applicable withholding taxes.
ON Semiconductor Connectivity Solutions, Inc.
Report date June 06, 2019 · Filed June 21, 2019
Section 16 reporting ended · disclosed 2019-06-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-06-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-06-04 · Gift · Disposed 1,634 · Balance 28,299 Row 2 · 2019-06-06 · Grant · Acquired 5,555 · Balance 33,854 F1: Each share is represented by a Restricted Stock Unit ("RSU"). 100% of the RSUs will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's 2020 Annual Meeting occurring after the grant date, in each case, subject to the Reporting Person's continued service as of the applicable vesting date and acceleration of vesting upon a change of control. Row 3 · 2019-06-19 · Disposition to issuer · Disposed 33,854 · Balance 0 F2: Each outstanding share of the Common Stock of the Issuer was converted into the right to receive $24.50 per share in cash, as described in the Merger Agreement. F3: Certain of these securities were RSUs that represented the Reporting Person's right to receive Common Stock shares of the Issuer. The RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive $24.50 per share in cash, as described in the Merger Agreement. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2026-07-13 | Direct | 0 |
Reported balance
After 2019-06-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-06-19 · Disposition to issuer · Disposed 72,000 · Balance 0 F4: Each outstanding option of the Issuer was either converted into the right to receive cash, or was cancelled without any cash payment or other consideration, as described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU"). 100% of the RSUs will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's 2020 Annual Meeting occurring after the grant date, in each case, subject to the Reporting Person's continued service as of the applicable vesting date and acceleration of vesting upon a change of control.
F2: Each outstanding share of the Common Stock of the Issuer was converted into the right to receive $24.50 per share in cash, as described in the Merger Agreement.
F3: Certain of these securities were RSUs that represented the Reporting Person's right to receive Common Stock shares of the Issuer. The RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive $24.50 per share in cash, as described in the Merger Agreement.
F4: Each outstanding option of the Issuer was either converted into the right to receive cash, or was cancelled without any cash payment or other consideration, as described in the Merger Agreement.
TUBEMOGUL INC
Report date December 19, 2016 · Filed December 21, 2016
Section 16 reporting ended · disclosed 2016-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,069 |
Reported balance
After 2016-12-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-12-19 · Other · Disposed 26,624 · Balance 8,069 F1: Of the reported shares, 8,069 shares are represented by RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-12-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2016-12-19 · Disposition to issuer · Disposed 8,069 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 10, 2016, by and among Issuer, Adobe Systems Incorporated, a Delaware corporation ("Adobe") and Tiger Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Adobe, the vesting of restricted stock units for an aggregate of 8,069 shares was accelerated immediately at the effective time of the Merger, and in accordance with the Merger Agreement, these accelerated restricted stock units were canceled and converted into the right to receive cash consideration of $14.00 per share, net to the seller in cash, without interest thereon and subject to any required tax withholding. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.37 · Expires 2025-06-18 | Direct | 0 |
Reported balance
After 2016-12-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-12-19 · Disposition to issuer · Disposed 5,679 · Balance 0 F3: This stock option is being canceled pursuant to the terms of the Merger Agreement. F4: This stock option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.76 · Expires 2023-11-11 | Direct | 0 |
Reported balance
After 2016-12-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-12-19 · Disposition to issuer · Disposed 107,500 · Balance 0 F5: Option is fully vested and immediately exercisable. Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and exercisable option to purchase shares of common stock of Issuer was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash equal to: (A) $14.00 per share minus (B) the exercise price per share of common stock of Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the reported shares, 8,069 shares are represented by RSUs.
F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 10, 2016, by and among Issuer, Adobe Systems Incorporated, a Delaware corporation ("Adobe") and Tiger Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Adobe, the vesting of restricted stock units for an aggregate of 8,069 shares was accelerated immediately at the effective time of the Merger, and in accordance with the Merger Agreement, these accelerated restricted stock units were canceled and converted into the right to receive cash consideration of $14.00 per share, net to the seller in cash, without interest thereon and subject to any required tax withholding.
F3: This stock option is being canceled pursuant to the terms of the Merger Agreement.
F4: This stock option is fully vested and exercisable.
F5: Option is fully vested and immediately exercisable. Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and exercisable option to purchase shares of common stock of Issuer was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash equal to: (A) $14.00 per share minus (B) the exercise price per share of common stock of Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 17:26 UTC | RESIDEO TECHNOLOGIES, INC. REZI · Entity 1292 | GrantCommon Stock | 1,811 | $17.96 | $32,525.56 |
DisclosureSEC source: 0001277624-26-000020 · wk-form4_1791221185.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,680 F1 · shares: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant. F2 · balance_after: Reflects 1,681 restricted stock units acquired pursuant to exempt anti-dilution adjustments in connection with the spin-off of ADI Global Distribution Inc. from Resideo Technologies, Inc. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 19:21 UTC | GLOBALFOUNDRIES Inc. GFS · Entity 3198 | GrantRestricted Share Units | 3,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001709048-26-000188 · wk-form4_1785439270.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,858 F1 · shares: Reflects restricted share units (RSUs) awarded on July 28, 2026 to the reporting person. Such RSUs vest on July 28, 2027, subject to the reporting person's continued service with the issuer through the vesting date. Each RSU represents a contingent right to receive one share of the issuer's ordinary shares upon settlement. F2 · balance_after: Represents 8,858 RSUs, 5,567 of which vest on July 29, 2026, and 3,291 of which vest on July 28, 2027, subject to the reporting person's continued service through each such vesting date. Each RSU represents a contingent right to receive one share of the issuer's ordinary shares upon settlement. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:15 UTC | RESIDEO TECHNOLOGIES, INC. REZI · Entity 1292 | GrantCommon Stock | 1,010 | $31.55 | $31,860.45 |
DisclosureSEC source: 0001277624-26-000017 · form4-07022026_080730.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,188 F1 · shares: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 23:08 UTC | BOX INC BOX · Entity 3932 | GrantClass A Common Stock | 8,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-288912 · ownership.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,727 F1 · shares: Represents an annual restricted stock unit ("RSU") award pursuant to the Issuer's Outside Director Compensation Policy. Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. 100% of the RSUs will vest on the earlier of (i) twelve months from date of grant (i.e. June 25, 2027) or (ii) the date of the Issuer's next annual meeting of stockholders. F2 · balance_after: Certain of these shares are represented by RSUs. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer subject to the applicable vesting schedule and the Reporting Person's continuous service through each such date. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 200 | $339.56 | $67,912.00 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 19 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,688 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F19 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 527 | $342.55 | $180,521.37 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 18 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,888 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F19 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 243 | $344.03 | $83,599.14 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 17 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,415 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F18 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $343.9250 to $344.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 246 | $345.24 | $84,928.20 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 16 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,658 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F17 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.6650 to $345.6250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 238 | $346.27 | $82,412.66 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 15 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,904 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.2700 to $346.6650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 193 | $347.84 | $67,132.91 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 14 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,142 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.7700 to $347.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 423 | $349.96 | $148,031.26 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 13 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,335 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $349.1050 to $350.0100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 17 | $351.13 | $5,969.21 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 12 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,758 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 318 | $351.72 | $111,846.55 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 11 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,775 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $351.5250 to $352.4850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,101 | $352.97 | $388,616.12 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 10 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,093 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $352.5400 to $353.5200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 373 | $354.38 | $132,185.19 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 9 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,194 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.0600 to $354.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 946 | $355.13 | $335,950.43 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 8 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,567 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.6200 to $355.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 566 | $356.94 | $202,030.42 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 7 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,513 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $356.6600 to $357.5750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 883 | $358.14 | $316,234.09 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 6 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,079 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $357.8650 to $358.6000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 877 | $359.33 | $315,129.52 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 5 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,962 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $358.8000 to $359.6400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,116 | $360.09 | $401,858.10 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 4 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,839 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $359.7450 to $360.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 854 | $361.11 | $308,384.61 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 3 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,955 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $360.8100 to $361.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 879 | $362.84 | $318,936.80 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 2 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,809 F3 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $362.5300 to $363.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | GrantCommon Stock | 837 | $0.00 | $0.00 |
DisclosureSEC source: 0001277624-26-000015 · wk-form4_1780964804.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,688 F1 · shares: These shares represent an award of restricted stock units ("RSUs") granted on June 4, 2026 (the "Grant Date") under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award vests in full upon the earlier of (i) the first anniversary of the Grant Date or (ii) the date of the next annual stockholder meeting of the Company following the Grant Date, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:30 UTC | RESIDEO TECHNOLOGIES, INC. REZI · Entity 1292 | GrantCommon Stock | 5,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001277624-26-000012 · form4-06052026_080639.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,178 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:30 UTC | RESIDEO TECHNOLOGIES, INC. REZI · Entity 1292 | GrantCommon Stock | 928 | $34.33 | $31,858.24 |
DisclosureSEC source: 0001277624-26-000010 · form4-04032026_040436.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,710 F1 · shares: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 22:26 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 2,500 | $130.00 | $325,000.00 |
DisclosureSEC source: 0001277624-26-000008 · wk-form4_1773786366.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,851 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:46 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 285 | $123.50 | $35,197.50 |
DisclosureSEC source: 0001277624-26-000006 · wk-form4_1773092771.xml · nonDerivative · entry 6 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,351 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:46 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 212 | $122.02 | $25,868.05 |
DisclosureSEC source: 0001277624-26-000006 · wk-form4_1773092771.xml · nonDerivative · entry 5 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,636 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.9100 to $122.0800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:46 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,035 | $121.30 | $125,550.26 |
DisclosureSEC source: 0001277624-26-000006 · wk-form4_1773092771.xml · nonDerivative · entry 4 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,848 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $120.8800 to $121.8000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:46 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,200 | $120.22 | $144,266.40 |
DisclosureSEC source: 0001277624-26-000006 · wk-form4_1773092771.xml · nonDerivative · entry 3 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,883 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.8100 to $120.7600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:46 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,167 | $119.49 | $378,435.60 |
DisclosureSEC source: 0001277624-26-000006 · wk-form4_1773092771.xml · nonDerivative · entry 2 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,083 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.7700 to $119.6700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:46 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,601 | $118.15 | $189,153.83 |
DisclosureSEC source: 0001277624-26-000006 · wk-form4_1773092771.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,250 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.6400 to $118.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:39 UTC | RESIDEO TECHNOLOGIES, INC. REZI · Entity 1292 | GrantCommon Stock | 901 | $35.36 | $31,859.36 |
DisclosureSEC source: 0001277624-26-000002 · form4-01052026_090121.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,782 F1 · shares: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 22:28 UTC | BOX INC BOX · Entity 3932 | SaleClass A Common Stock | 2,500 | $31.77 | $79,420.00 |
DisclosureSEC source: 0001193125-25-309974 · ownership.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,355 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $31.61 to $32.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Certain of these shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer subject to the applicable vesting schedule and the Reporting Person's continuous service through each such date. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 296 | $159.09 | $47,090.55 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 9 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,851 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.0750 to $159.1050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 286 | $157.85 | $45,144.36 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 8 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,147 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.4800 to $158.2200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 159 | $154.08 | $24,499.17 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 7 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,433 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.0000 to $154.9800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 166 | $152.67 | $25,343.22 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 6 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,592 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 219 | $149.17 | $32,668.23 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 5 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,758 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 168 | $147.58 | $24,792.60 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 4 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,977 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.1800 to $147.9700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 577 | $145.97 | $84,226.59 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 3 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,145 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.7200 to $146.2600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 461 | $143.60 | $66,200.06 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 2 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,722 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.2800 to $143.7650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 21:10 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 168 | $142.31 | $23,908.50 |
DisclosureSEC source: 0001277624-25-000007 · wk-form4_1763759454.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,183 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.0850 to $142.5400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:15 UTC | RESIDEO TECHNOLOGIES, INC. REZI · Entity 1292 | GrantCommon Stock | 747 | $42.68 | $31,878.23 |
DisclosureSEC source: 0001277624-25-000005 · form4-10032025_081035.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,881 F1 · shares: Issued under the 2018 Stock Plan for Non-Employee Directors of Resideo Technologies, Inc. in lieu of annual cash retainer fees and to be settled by issuance of shares of Common Stock in a lump sum following termination of service as a director. These stock units are fully vested upon grant. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 21:31 UTC | BOX INC BOX · Entity 3932 | SaleClass A Common Stock | 5,000 | $32.20 | $160,975.00 |
DisclosureSEC source: 0001193125-25-225307 · ownership.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,855 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $32.09 to $32.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Certain of these shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer subject to the applicable vesting schedule and the Reporting Person's continuous service through each such date. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 23:24 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 73 | $183.09 | $13,365.59 |
DisclosureSEC source: 0001736297-25-000122 · wk-form4_1756423455.xml · nonDerivative · entry 5 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,351 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $182.3100 to $183.2000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 23:24 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 3,450 | $179.79 | $620,270.33 |
DisclosureSEC source: 0001736297-25-000122 · wk-form4_1756423455.xml · nonDerivative · entry 4 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,424 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $179.3800 to $180.1100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 23:24 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 8,706 | $178.83 | $1,556,853.06 |
DisclosureSEC source: 0001736297-25-000122 · wk-form4_1756423455.xml · nonDerivative · entry 3 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,874 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.3200 to $179.3050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 23:24 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 8,718 | $177.73 | $1,549,440.55 |
DisclosureSEC source: 0001736297-25-000122 · wk-form4_1756423455.xml · nonDerivative · entry 2 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,580 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $177.3100 to $178.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 23:24 UTC | Astera Labs, Inc. ALAB · Entity 1853 | SaleCommon Stock | 1,553 | $176.73 | $274,468.21 |
DisclosureSEC source: 0001736297-25-000122 · wk-form4_1756423455.xml · nonDerivative · entry 1 LAZAR JACK R · CIK 0001277624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,298 F1 · kind: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $176.2100 to $177.0500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.